Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

被引：85

作者：

Frogel, M. ^{[1
]}

Nerwen, C. ^{[1
]}

Cohen, A. ^{[2
]}

VanVeldhuisen, P. ^{[3
]}

Harrington, M. ^{[3
]}

Boron, M. ^{[2
]}

机构：

[1] Schneider Childrens Hosp, Div Gen Pediat, New Hyde Pk, NY 11042 USA

[2] Medimmune Inc, Med & Sci Affairs, Gaithersburg, MD 20878 USA

[3] EMMES Corp, Synagis Outcomes Registry Coordinating Ctr, Rockville, MD USA

来源：

JOURNAL OF PERINATOLOGY | 2008年 / 28卷 / 07期

关键词：

bronchiolitis; palivizumab; pediatrics; prophylaxis; prematurity; respiratory syncytial virus;

D O I：

10.1038/jp.2008.28

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness. Study Design: Prospective observational registry enrolling those who received >= 1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites. Result: Of 19 548 subjects enrolled, 40% were born before 32 weeks', 48% between 32 and 35 weeks' and 12% after 35 weeks' gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age < 32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and > 2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates. Conclusion: Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.

引用

页码：511 / 517

页数：7

共 29 条

[1]

Abramson JS, 2003, PEDIATRICS, V112, P1442

[2]

[Anonymous], 1998, Pediatrics, V102, P1211

[3] Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid [J].

Boyce, TG ;

Mellen, BG ;

Mitchel, EF ;

Wright, PF ;

Griffin, MR .

JOURNAL OF PEDIATRICS, 2000, 137 (06) :865-870

[4] Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation:: a prospective study [J].

Carbonell-Estrany, X ;

Quero, J ;

Bustos, G ;

Cotero, A ;

Doménech, E ;

Figueras-Aloy, J ;

Fraga, JM ;

García, LG ;

García-Alix, A ;

Del Río, MG ;

Krauel, X ;

Sastre, JBL ;

Narbona, E ;

Roqués, V ;

Hernández, SS ;

Zapatero, M .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (07) :592-597

[5]

*CDCP, 2001, MMWR-MORBID MORTAL W, V51, P26

[6]

COHEN AH, 2000, J RESP DIS S, V2, pS30

[7] Palivizumab use in subjects with congenital heart disease: Results from the 2000-2004 Palivizumab Outcomes Registry [J].

Cohen S.A. ;

Zanni R. ;

Cohen A. ;

Harrington M. ;

Vanveldhuisen P. ;

Boron M.L. .

Pediatric Cardiology, 2008, 29 (2) :382-387

[8] Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease [J].

Feltes, TF ;

Cabalka, AK ;

Meissner, C ;

Piazza, FM ;

Carlin, DA ;

Top, FH ;

Connor, EM ;

Sondheimer, HM .

JOURNAL OF PEDIATRICS, 2003, 143 (04) :532-540

[9] Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain [J].

Figueras-Aloy, J ;

Carbonell-Estrany, X ;

Quero, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (09) :815-820

[10] Risk factors for bronchiolitis-associated deaths among infants in the United States [J].

Holman, RC ;

Shay, DK ;

Curns, AT ;

Lingappa, JR ;

Anderson, LJ .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (06) :483-489

← 1 2 3 →